Tuesday Mar 4
AVEO Announces Timing for Conference Call to Discuss Year-End 2013...
AVEO Oncology today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014.
Catabasis Pharmaceuticals, Inc. Announces Appointment Of As Independent Director
Mr. Bate is an experienced biotechnology executive having led companies at various stages of development.
AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.),...
AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer CAMBRIDGE, Mass., Jan 30, 2014 -- AVEO Oncology AVEO -10.73% today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast ... (more)
Stocks Posting Big Declines: NASDAQ:NVGN, NASDAQ:AVEO, NASDAQ:MOBI, NYSE:FENG
Novogen Limited is -0.04 - -0.93% from the previous close of $4.28. It traded between $4.24 - 4.24 with total traded volume of 100 shares.
Aveo gets end-of-the-year stock surge with new major stakeholder
After a dismal year for Aveo Pharmaceuticals , in which stock value plunged 80 percent, the cancer biotech got an end-of-the-year stock uptick this week when a Connecticut investment firm with experience in buying out life science companies disclosed a 5.7 percent stake in the company.